Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT

Lawrence H. Einhorn, Mary J. Brames, Michael C. Heinrich, Christopher L. Corless, Ali Madani

Research output: Contribution to journalArticle

74 Scopus citations

Fingerprint Dive into the research topics of 'Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT'. Together they form a unique fingerprint.

Medicine & Life Sciences